^
Association details:
| Biomarker: | EZH2 Y646F |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Tazverik (tazemetostat) (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Excerpt:
Treatment of EZH2-mutant NHL xenograft-bearing mice with EPZ-6438 causes dose-dependent tumor growth inhibition, including complete and sustained tumor regressions with correlative diminution of H3K27Me3 levels in tumors and selected normal tissues. Mice dosed orally with EPZ-6438 for 28 days remained tumor free for up to 63 days after stopping compound treatment in two EZH2-mutant xenograft models.
DOI:
10.1158/1535-7163.MCT-13-0773
